238 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Range Financial Group LLC

Range Financial Group LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the first quarter, HoldingsChannel.com reports. The firm purchased 238 shares of the biopharmaceutical company’s stock, valued at approximately $229,000.

Other large investors have also bought and sold shares of the company. Stifel Financial Corp increased its position in Regeneron Pharmaceuticals by 12.2% in the 3rd quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock valued at $25,537,000 after acquiring an additional 3,385 shares in the last quarter. Sierra Summit Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $1,011,000. LPL Financial LLC raised its position in Regeneron Pharmaceuticals by 9.3% in the 3rd quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock worth $33,522,000 after purchasing an additional 3,479 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth $749,000. Finally, Public Employees Retirement Association of Colorado boosted its position in Regeneron Pharmaceuticals by 16.0% in the 4th quarter. Public Employees Retirement Association of Colorado now owns 16,074 shares of the biopharmaceutical company’s stock valued at $14,118,000 after buying an additional 2,220 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 787 shares of the stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $1,015.02, for a total value of $798,820.74. Following the completion of the transaction, the chief executive officer now directly owns 64,198 shares in the company, valued at $65,162,253.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 787 shares of the company’s stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $1,015.02, for a total value of $798,820.74. Following the completion of the transaction, the chief executive officer now directly owns 64,198 shares in the company, valued at approximately $65,162,253.96. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Michael S. Brown sold 1,172 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,347,256.52. The disclosure for this sale can be found here. Insiders have sold 61,215 shares of company stock worth $60,414,782 in the last 90 days. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $1,063.89 on Tuesday. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $117.23 billion, a PE ratio of 31.43, a price-to-earnings-growth ratio of 2.18 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $1,068.00. The stock’s 50-day simple moving average is $971.15 and its 200 day simple moving average is $945.80.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The company had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Truist Financial reaffirmed a “buy” rating and set a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. UBS Group boosted their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. TD Cowen raised their price objective on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Royal Bank of Canada reiterated an “outperform” rating and set a $1,229.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday. Finally, Morgan Stanley lifted their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $998.09.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.